Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Cash from Financing Activities (2016 - 2023)

Historic Cash from Financing Activities for Aptevo Therapeutics (APVO) over the last 9 years, with Q3 2023 value amounting to $4.3 million.

  • Aptevo Therapeutics' Cash from Financing Activities rose 96880.0% to $4.3 million in Q3 2023 from the same period last year, while for Sep 2023 it was $9.0 million, marking a year-over-year increase of 17656.12%. This contributed to the annual value of $6.0 million for FY2023, which is 32928.13% up from last year.
  • Aptevo Therapeutics' Cash from Financing Activities amounted to $4.3 million in Q3 2023, which was up 96880.0% from $481000.0 recorded in Q2 2023.
  • Over the past 5 years, Aptevo Therapeutics' Cash from Financing Activities peaked at $24.7 million during Q3 2020, and registered a low of -$22.1 million during Q1 2020.
  • Its 5-year average for Cash from Financing Activities is $3.9 million, with a median of -$44500.0 in 2019.
  • Data for Aptevo Therapeutics' Cash from Financing Activities shows a peak YoY increase of 10294166.67% (in 2020) and a maximum YoY decrease of 20849.65% (in 2020) over the last 5 years.
  • Over the past 5 years, Aptevo Therapeutics' Cash from Financing Activities (Quarter) stood at -$135000.0 in 2019, then skyrocketed by 15839.26% to $21.2 million in 2020, then crashed by 114.48% to -$3.1 million in 2021, then surged by 294.99% to $6.0 million in 2022, then fell by 27.58% to $4.3 million in 2023.
  • Its Cash from Financing Activities stands at $4.3 million for Q3 2023, versus $481000.0 for Q2 2023 and -$1.9 million for Q1 2023.